COMPUMED, INC. EXPANDS GLOBAL DISTRIBUTION OF OSTEOGRAMŽ IMAGING SYSTEM
New Distribution Partners Added in Europe and the Middle East
LOS ANGELES, July 27, 2004 -- CompuMed, Inc. (CMPD.OB) -- a medical informatics company serving the healthcare community with diagnostic software solutions -- today announced that it has partnered with seven additional, highly experienced medical imaging product distributors to expand worldwide sales of its OsteoGram osteoporosis imaging system. With OsteoGram sales already growing in Asia and North America, the new distributors will be charged specifically with launching sales efforts in Europe and expanding existing sales in the Middle East.
The new distributors represent the United Kingdom, the Netherlands, France, Italy, Austria, the Czech Republic, Turkey and Iran. They recently attended a CompuMed sales training program in Prague, where they were briefed on the OsteoGram system and its unique, low-cost technology for osteoporosis screening, monitoring and diagnostics.
"We are pleased to join forces with our new distribution partners to enter the European market and expand existing sales in the Middle East," said Jerry McLaughlin, CompuMed's CEO. "Europe is rapidly adopting digital X-ray equipment, and our team of experienced distributors understands the market's need for CAD solutions such as the OsteoGram."
The OsteoGram is a software-based imaging system that enables healthcare providers to screen, diagnose and monitor osteoporosis using a conventional film-based hand x-ray or digital image derived from filmless x-ray equipment.
CompuMed recently introduced a DICOM (Digital Communications and Imaging in Medicine) compliant version of the OsteoGram for use on digital imaging platforms. DICOM is the international information standard that allows the new generation of medical imaging equipment to interconnect. Systems based on the standard have become a high growth segment of the global medical imaging market. The new DICOM version of the OsteoGram enables healthcare professionals who perform osteoporosis screening to achieve workstation consolidation by eliminating the need for dedicated and expensive equipment, computers, office space and staff.
"I look forward to the results that will be achieved by our new partners in key international markets," McLaughlin said. "Several have existing distribution agreements with digital radiography manufacturers that will complement our efforts, and two have already initiated marketing trials in their respective countries."
About CompuMed:
Founded in 1973, CompuMed, Inc. (OTC Bulletin Board: CMPD) is a leading provider of computer-aided telemedicine and diagnostics technology. The company's core products are the OsteoGramŽ and CardioGram systems. The OsteoGram, which is cleared by the FDA for commercial use, is an accurate and precise technology for low-cost osteoporosis testing. The CardioGram system remotely interprets electrocardiograms and is used by private practice, government and corporate healthcare providers nationwide. The CardioGram also has the capability to automatically provide an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles. Visit CompuMed at www.compumed.net.
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks defined in this document. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
CONTACT: Erik Deutsch - Tellem Worldwide, +1 (310) 479-6111 x.15, edeutsch@tellem.com